Prelude Capital Management’s Terns Pharmaceuticals TERN Stock Holding History

Prelude Capital Management’s Portfolio TERN Stock Details TERN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-54,825	Closed	-$2.89M	–	1525
2026 Q1	$2.89M	Buy	+54,825	New	+$2.25M	0.22%	111
2025 Q2	–	Sell	-17,500	Closed	-$48.3K	–	1347
2025 Q1	$48.3K	Buy	+17,500	New	+$71.5K	﹤0.01%	1094
2024 Q4	–	Sell	-18,778	Closed	-$157K	–	1559
2024 Q3	$157K	Sell	18,778 -13,309	-41%	-$110K	0.01%	1101
2024 Q2	$219K	Sell	32,087 -52,532	-62%	-$318K	0.02%	949
2024 Q1	$555K	Buy	+84,619	New	+$553K	0.03%	592
2022 Q4	–	Sell	-10,945	Closed	-$64K	–	1607
2022 Q3	$64K	Buy	+10,945	New	+$40.7K	﹤0.01%	1213

Other funds holding TERN

IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

Prelude Capital Management's TERN Position: Q2 2026 in Review

Prelude Capital Management sold out of Terns Pharmaceuticals (TERN) in Q2 2026, closing a stake of 54,825 shares — an estimated $2.89M sold.

Prelude Capital Management first reported a position in TERN in Q3 2022 and held it in 6 quarters. The position peaked at $2.89M in Q1 2026. 1 fund tracked by Wall St. Rank holds TERN as of Q2 2026.

Prelude Capital Management reported no remaining Terns Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
Prelude Capital Management sold 54,825 Terns Pharmaceuticals shares in Q2 2026, an estimated $2.89M.
Prelude Capital Management first reported a position in Terns Pharmaceuticals in Q3 2022 and held it in 6 quarters.
Prelude Capital Management's Terns Pharmaceuticals position peaked at $2.89M in Q1 2026.
1 fund tracked by Wall St. Rank held Terns Pharmaceuticals as of Q2 2026.

Based on Prelude Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.